陇神戎发：血液透析干粉取得医疗器械注册证

Group 1 - The core point of the article is that Longshen Rongfa has received a medical device registration certificate for its "blood dialysis dry powder" from the National Medical Products Administration of China [1] - As of the first half of 2025, Longshen Rongfa's revenue composition is as follows: 86.53% from pharmaceutical sales, 6.69% from medical device sales, 4.48% from logistics distribution, 0.76% from property leasing, and 0.7% from consulting services [1] - The current market capitalization of Longshen Rongfa is 3.1 billion yuan [1]